Integer (NYSE:ITGR) Price Target Raised to $110.00

Integer (NYSE:ITGR) had its price objective increased by Truist Financial from $97.00 to $110.00 in a report issued on Thursday, MarketBeat Ratings reports. The firm currently has a buy rating on the medical equipment provider’s stock.

Other equities research analysts have also issued research reports about the company. Zacks Research lowered Integer from a “hold” rating to a “strong sell” rating in a research report on Monday, May 11th. Citigroup increased their price target on shares of Integer from $92.00 to $96.00 and gave the stock a “neutral” rating in a report on Wednesday, July 8th. Weiss Ratings reissued a “hold (c)” rating on shares of Integer in a research report on Thursday, June 18th. Finally, Piper Sandler restated an “overweight” rating and set a $97.00 price objective (up from $87.00) on shares of Integer in a research note on Friday, May 1st. Four analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $101.14.

Integer Price Performance

NYSE ITGR opened at $95.56 on Thursday. The company has a market cap of $3.25 billion, a price-to-earnings ratio of 23.83, a PEG ratio of 2.27 and a beta of 0.64. The company has a debt-to-equity ratio of 0.77, a current ratio of 3.75 and a quick ratio of 2.38. The stock’s fifty day moving average price is $91.53 and its 200 day moving average price is $87.50. Integer has a 1 year low of $62.00 and a 1 year high of $116.31.

Integer (NYSE:ITGR) last posted its quarterly earnings results on Thursday, April 30th. The medical equipment provider reported $1.20 earnings per share for the quarter, missing the consensus estimate of $1.21 by ($0.01). The firm had revenue of $439.58 million for the quarter, compared to analysts’ expectations of $426.48 million. Integer had a net margin of 7.64% and a return on equity of 12.83%. The firm’s revenue for the quarter was up .5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.31 EPS. Integer has set its FY 2026 guidance at 5.830-6.400 EPS. As a group, equities research analysts forecast that Integer will post 6.04 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Heartland Advisors Inc. increased its holdings in shares of Integer by 506.8% during the 4th quarter. Heartland Advisors Inc. now owns 242,715 shares of the medical equipment provider’s stock valued at $19,036,000 after purchasing an additional 202,715 shares in the last quarter. Tudor Investment Corp ET AL increased its holdings in Integer by 50,787.5% in the third quarter. Tudor Investment Corp ET AL now owns 29,500,000 shares of the medical equipment provider’s stock valued at $28,606,000 after buying an additional 29,442,029 shares in the last quarter. WINTON GROUP Ltd purchased a new position in Integer in the fourth quarter valued at $4,836,000. Jennison Associates LLC acquired a new position in shares of Integer in the fourth quarter worth about $1,036,000. Finally, Kestrel Investment Management Corp acquired a new position in shares of Integer in the fourth quarter worth about $5,933,000. 99.29% of the stock is currently owned by hedge funds and other institutional investors.

About Integer

Integer Holdings Corporation (NYSE: ITGR) is a global provider of outsourced medical device design, development and manufacturing solutions. The company partners with leading medical technology firms to deliver complex components, subsystems and finished devices across a range of therapeutic areas. Its services encompass concept and product design, precision machining, microelectronic assembly, terminal sterilization and regulatory support, enabling customers to accelerate time to market and optimize product performance.

Integer’s product portfolio is organized into two core segments: Advanced Delivery and MedTech.